Table 3.
Expression of p27Kip1, MIB1, and p53 in 10 Cases of Blastic Variant of MCL
| Case | Diagnosis | p27* | MiB1 | p53 |
|---|---|---|---|---|
| 1 | MCL-blastic | − | 83% | 20% |
| 2 | MCL-blastic | − | 80% | 20% |
| 3 | MCL-blastic | + | 70% | >80% |
| 4 | MCL-blastic | ++ | 100% | 20% |
| 5 | MCL-blastic | + | 50% | >80% |
| 6 | MCL-blastic | + | 95% | <5% |
| 7 | MCL-blastic | + | 76% | 0%† |
| 8 | MCL-blastic | + | 32% | 50% |
| 9 | MCL-blastic | + | 50% | >80% |
| 10 | MCL-blastic | + | 48% | 0%‡ |
*+, most tumor cells faintly positive and less intense than T lymphocytes; ++, most tumor cells positive with equal intensity as T lymphocytes.
†In this case a homozygous deletion of p16 was detected by Southern blot.
‡In this case a hemizygous deletion of p16 was detected by cytogenetic analysis:del (9) (p12).